Platelets as biomarkers of coronary artery disease

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 3, 2016, Pages 223-233

  Pasalic, Leonardo ^a,b   Wang, Samuel S Y ^c   Chen, Vivien M Y ^a,c,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ANZAC RESEARCH INSTITUTE   (Australia)

^d Concord Repatriation and General Hospital ^*  (Australia)

Author keywords

biomarker; cardiovascular disease; platelet function; platelets

Indexed keywords

BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; BLOOD CLOTTING; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FUNCTIONAL STATUS; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; PLATELET REACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION; STENT THROMBOSIS; SUDDEN CARDIAC DEATH; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; ATHEROSCLEROSIS; BIOLOGICAL MODEL; BLOOD; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; THROMBOSIS;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BIOMARKERS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; HUMANS; MODELS, CARDIOVASCULAR; PLATELET COUNT; RISK FACTORS; THROMBOSIS;

EID: 84962799602     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1572328     Document Type: Article

References (132)

1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet: 2012; 380 9859 2095 2128
2. Jackson S. P. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med: 2011; 17 11 1423 1436
3. Montgomery J. E., Brown J. R. Metabolic biomarkers for predicting cardiovascular disease. Vasc Health Risk Manag: 2013; 9 37 45
4. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation: 2005; 111 25 3481 3488
5. Versteeg H. H., Heemskerk J. WM, Levi M., Reitsma P. H. New fundamentals in hemostasis. Physiol Rev: 2013; 93 1 327 358
6. Monroe D. M., Hoffman M., Roberts H. R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol: 2002; 22 9 1381 1389
7. Monroe D. M., Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol: 2006; 26 1 41 48
8. Hoffman M., Monroe D. M. III. A cell-based model of hemostasis. Thromb Haemost: 2001; 85 6 958 965
9. Heemskerk J. WM, Mattheij N. JA, Cosemans J. MEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost: 2013; 11 1 2 16
10. Kuijpers M. JE, Munnix I. C., Cosemans J. M., et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation: 2008; 15 4 269 282
11. Bennett J. S. Platelet-fibrinogen interactions. Ann N Y Acad Sci: 2001; 936 340 354
12. Alshehri O. M., Hughes C. E., Montague S., et al. Fibrin activates GPVI in human and mouse platelets. Blood: 2015; 126 13 1601 1608
13. Ferroni P., Vazzana N., Riondino S., Cuccurullo C., Guadagni F., Davì G. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal: 2012; 17 10 1447 1485
14. Swieringa F., Kuijpers M. JE, Heemskerk J. WM, van der Meijden P. EJ. Targeting platelet receptor function in thrombus formation: the risk of bleeding. Blood Rev: 2014; 28 1 9 21
15. Koyama H., Maeno T., Fukumoto S., et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation: 2003; 108 5 524 529
16. Gawaz M., Langer H., May A. E. Platelets in inflammation and atherogenesis. J Clin Invest: 2005; 115 12 3378 3384
17. Huo Y., Schober A., Forlow S. B., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med: 2003; 9 1 61 67
18. Davì G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med: 2007; 357 24 2482 2494
19. Vorchheimer D. A., Becker R. Platelets in atherothrombosis. Mayo Clin Proc: 2006; 81 1 59 68
20. Sharma G., Berger J. S. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis: 2011; 32 2 201 208
21. D'Agostino R. B. Sr, Grundy S., Sullivan L. M., Wilson P.; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA: 2001; 286 2 180 187
22. Lerner D. J., Kannel W. B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J: 1986; 111 2 383 390
23. Wilson P. W., Pencina M., Jacques P., Selhub J., D'Agostino R. Sr, O'Donnell C. J. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes: 2008; 1 2 92 97
24. Akosah K. O., Schaper A., Cogbill C., Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol: 2003; 41 9 1475 1479
25. Falk E., Sillesen H., Muntendam P., Fuster V. The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population. Curr Atheroscler Rep: 2011; 13 5 359 366
26. Fernández-Ortiz A., Jiménez-Borreguero L. J., Peñalvo J. L., et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J: 2013; 166 6 990 998
27. Budoff M. J., Diamond G. A., Raggi P., et al. Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation: 2002; 105 15 1791 1796
28. Eapen D. J., Ghasemzadeh N., MacNamara J. P., Quyyumi A. The evaluation of novel biomarkers and the multiple biomarker approach in the prediction of cardiovascular disease. Curr Cardiovasc Risk Rep: 2014; 8 408 411
29. Aldous S. J. Cardiac biomarkers in acute myocardial infarction. Int J Cardiol: 2013; 164 3 282 294
30. Liuzzo G., Biasucci L. M., Gallimore J. R., et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol: 1999; 34 6 1696 1703
31. Arroyo-Espliguero R., Avanzas P., Cosín-Sales J., Aldama G., Pizzi C., Kaski J. C. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J: 2004; 25 5 401 408
32. Kervinen H., Palosuo T., Manninen V., Tenkanen L., Vaarala O., Mänttäri M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J: 2001; 141 4 580 585
33. Ridker P. M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation: 2001; 103 13 1813 1818
34. Koenig W., Löwel H., Baumert J., Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation: 2004; 109 11 1349 1353
35. Ridker P. M., Danielson E., Fonseca F. A., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med: 2008; 359 21 2195 2207
36. Kaptoge S., Di Angelantonio E., Pennells L., et al. Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med: 2012; 367 14 1310 1320
37. Di Angelantonio E., Gao P., Pennells L., et al. Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA: 2012; 307 23 2499 2506
38. Looney S. W., Hagan J. L. Statistical methods for assessing biomarkers and analyzing biomarker data. In: Rao C. R., Miller J., Rao D. C. eds. Handbook of Statistics. Volume 27. Elsevier: 2007; 109 147
39. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx: 2004; 1 2 182 188
40. Strimbu K., Tavel J. A. What are biomarkers? Curr Opin HIV AIDS: 2010; 5 6 463 466
41. Hoefer I. E., Sels J. W., Jukema J. W., et al. Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clin Res Cardiol: 2013; 102 11 847 856
42. Kang J-G, Patino W. D., Matoba S., Hwang P. M. Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med: 2006; 16 5 163 168
43. Lindsay C. R., Edelstein L. C. MicroRNAs in platelet physiology and function. Semin Thromb Hemost: 2016; 42 3 215 222
44. Wykrzykowska J. J., Garcia-Garcia H. M., Goedhart D., Zalewski A., Serruys P. W. Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol: 2011; 149 1 10 16
45. Bahou W. F. Genetic dissection of platelet function in health and disease using systems biology. Hematol Oncol Clin North Am: 2013; 27 3 443 463
46. Tchebiner J. Z., Nutman A., Boursi B., et al. Diagnostic and prognostic value of thrombocytosis in admitted medical patients. Am J Med Sci: 2011; 342 5 395 401
47. van der Bom J. G., Heckbert S. R., Lumley T., et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost: 2009; 7 3 399 405
48. Gary T., Pichler M., Belaj K., et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS ONE: 2013; 8 7 e67688
49. Ozcan Cetin E. H., Cetin M. S., Aras D., et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST-segment elevation myocardial infarction (epub ahead of print). Angiology 2015;pii: 0003319715591751; doi: 10.1177/0003319715591751
50. Oylumlu M., Ylldlz A., Oylumlu M., et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol: 2015; 15 4 277 283
51. Kurtul A., Murat S. N., Yarlioglues M., et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol: 2014; 114 7 972 978
52. Panova-Noeva M., Schulz A., Hermanns M. I., Grossmann V., Pefani E., Spronk H. MH., et al. Sex-specific differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study. Blood: 2016; 127 2 251 259
53. Goncalves S. C., Labinaz M., Le May M., et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol: 2011; 107 2 204 209
54. Ju H. Y., Kim J. K., Hur S. M., et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease? Platelets: 2015; 26 2 143 147
55. Ki Y. J., Park S., Ha S. I., Choi D. H., Song H. Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: a comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide. Platelets: 2014; 25 6 427 432
56. Lai H. M., Xu R., Yang Y. N., et al. Association of mean platelet volume with angiographic thrombus burden and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv: 2015; 85 01 724 733
57. Khandekar M. M., Khurana A. S., Deshmukh S. D., Kakrani A. L., Katdare A. D., Inamdar A. K. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol: 2006; 59 2 146 149
58. Guthikonda S., Lev E. I., Patel R., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost: 2007; 5 3 490 496
59. Guthikonda S., Alviar C. L., Vaduganathan M., et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol: 2008; 52 9 743 749
60. Chu S. G., Becker R. C., Berger P. B., et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost: 2010; 8 1 148 156
61. Tavil Y., Sen N., Yazici H. U., Hizal F., Abaci A., Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res: 2007; 120 2 245 250
62. Kamath S., Blann A. D., Lip G. Y. Platelet activation: assessment and quantification. Eur Heart J: 2001; 22 17 1561 1571
63. Zhang Y., et al. Reticulated platelets are associated with long-term outcomes of premature coronary artery disease following percutaneous coronary intervention. Experimental and Clinical Cardiology: 2014; 20 145 163
64. Ibrahim H., Schutt R. C., Hannawi B., DeLao T., Barker C. M., Kleiman N. S. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol: 2014; 64 20 2122 2129
65. Rinder H. M., Schuster J. E., Rinder C. S., Wang C., Schweidler H. J., Smith B. R. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood: 1998; 91 4 1288 1294
66. Wiviott S. D., Steg P. G. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet: 2015; 386 9990 292 302
67. Freynhofer M. K., Bruno V., Wojta J., Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des: 2012; 18 33 5197 5214
68. Eikelboom J. W., Hirsh J., Spencer F. A., Baglin T. P., Weitz J. I. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e89S e119S
69. Osnabrugge R. L., Head S. J., Zijlstra F., et al. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med: 2015; 17 1 3 11
70. Patrono C., García Rodríguez L. A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med: 2005; 353 22 2373 2383
71. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 2002; 324 7329 71 86
72. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet: 1998; 351 9098 233 241
73. Mangiacapra F., Barbato E., Patti G., et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv: 2010; 3 3 318 323
74. Zhao X. Y., Wang X. F., Zhang J. Y., Du Y. Y., Yang H. B. Effect of the composition of atherosclerotic plaques and rate of platelet aggregation on elevation of serum levels of cardiac troponin T after percutaneous coronary interventions. J Interv Cardiol: 2012; 25 5 433 438
75. Zhang H. Z., Kim M. H., Jeong Y. H. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets: 2014; 25 4 292 299
76. Patti G., Mangiacapra F., Ricottini E., et al. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). Am J Cardiol: 2013; 111 12 1739 1744
77. Mangiacapra F., Bartunek J., Bijnens N., et al. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost: 2012; 10 12 2452 2461
78. Park D. W., Ahn J. M., Song H. G., et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J: 2013; 165 1 34 42.e1
79. Mangiacapra F., Peace A., Barbato E., et al. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets: 2014; 25 5 348 356
80. Mehta S. R., Bassand J. P., Chrolavicius S., et al. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med: 2010; 363 10 930 942
81. Kim C., Ye F., Ginsberg M. H. Regulation of integrin activation. Annu Rev Cell Dev Biol: 2011; 27 321 345
82. Kasirer-Friede A., Kahn M. L., Shattil S. J. Platelet integrins and immunoreceptors. Immunol Rev: 2007; 218 247 264
83. Berny-Lang M. A., Frelinger A. L. III, Barnard M. R., Michelson A. D. In: Michelson A. D. ed. Platelets. 3rd ed. London Academic Press: 2013; 581 602
84. McEver R. P., Cummings R. D. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest: 1997; 100 3 485 491
85. Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest: 1997; 100 (11, Suppl): S31 S35
86. Yang J., Furie B. C., Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost: 1999; 81 1 1 7
87. Evangelista V., Smyth S. S. Platelets. 3rd ed. In: Michelson A. D. ed. London Academic Press: 2013; 295 312
88. Massaguer A., Engel P., Pérez-del-Pulgar S., Bosch J., Pizcueta P. Production and characterization of monoclonal antibodies against conserved epitopes of P-selectin (CD62P). Tissue Antigens: 2000; 56 2 117 128
89. Ramström S., Södergren A. L., Tynngård N., Lindahl T. L. Platelet function determined by flow cytometry: new perspectives? Semin Thromb Hemost: 2016; 42 3 268 281
90. Klinkhardt U., Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Semin Thromb Hemost: 2005; 31 4 400 403
91. Granja T., Schad J., Schüssel P., et al. Using six-colour flow cytometry to analyse the activation and interaction of platelets and leukocytes-A new assay suitable for bench and bedside conditions. Thromb Res: 2015; 136 4 786 796
92. Barnard M. R., Krueger L. A., Frelinger A. L., Furman M. I., Michelson A. D. Whole blood analysis of leukocyte-platelet aggregates. Current protocols in cytometry: 2003; 24 6.15:6.15.1-6.15.8; DOI: 10.1002/0471142956.cy0615s24
93. Xu X. X., Gao X. H., Pan R., Lu D., Dai Y. A simple adhesion assay for studying interactions between platelets and endothelial cells in vitro. Cytotechnology: 2010; 62 1 17 22
94. Tantry U. S., Bliden K. P., Suarez T. A., Kreutz R. P., Dichiara J., Gurbel P. A. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets: 2010; 21 5 360 367
95. Schultheiss H. P., Tschoepe D., Esser J., et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest: 1994; 24 4 243 247
96. Yip H-K, Chang L. T., Sun C. K., et al. Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J: 2006; 70 1 31 36
97. Coulter S. A., Cannon C. P., Ault K. A., et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation: 2000; 101 23 2690 2695
98. Furman M. I., Benoit S. E., Barnard M. R., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol: 1998; 31 2 352 358
99. Kappelmayer J., Nagy B. Jr, Miszti-Blasius K., Hevessy Z., Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med: 2004; 42 5 475 486
100. Tschoepe D., Schultheiss H. P., Kolarov P., et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation: 1993; 88 1 37 42
101. Gawaz M., Neumann F. J., Ott I., May A., Rüdiger S., Schömig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis: 1997; 8 3-4 121 128
102. Kabbani S. S., Watkins M. W., Ashikaga T., et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation: 2001; 104 2 181 186
103. Kabbani S. S., Watkins M. W., Ashikaga T., Terrien E. F., Sobel B. E., Schneider D. J. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol: 2003; 91 7 876 878
104. Ault K. A., Cannon C. P., Mitchell J., et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol: 1999; 33 3 634 639
105. Frelinger A. L. III, Michelson A. D., Wiviott S. D., et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost: 2011; 106 2 219 226
106. Gawaz M., Neumann F. J., Ott I., May A., Schömig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation: 1996; 94 3 279 285
107. Neumann F. J., Gawaz M., Dickfeld T., et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol: 1997; 29 7 1515 1519
108. Floyd C. N., Goodman T., Becker S., et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br J Clin Pharmacol: 2014; 78 2 320 328
109. Trip M. D., Cats V. M., van Capelle F. J., Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med: 1990; 322 22 1549 1554
110. Vanschoonbeek K., Feijge M. A., Keuren J. F., et al. Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation. Thromb Haemost: 2002; 88 6 931 937
111. Konstantopoulos K., Grotta J. C., Sills C., Wu K. K., Hellums J. D. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost: 1995; 74 5 1329 1334
112. Yee D. L., Sun C. W., Bergeron A. L., Dong J. F., Bray P. F. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood: 2005; 106 8 2723 2729
113. Qayyum R., Becker D. M., Yanek L. R., et al. Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes. Clin Transl Sci: 2015; 8 1 17 22
114. McBane R. D. II, Karnicki K., Tahirkheli N., Miller R. S., Owen W. G. Platelet characteristics associated with coronary artery disease. J Thromb Haemost: 2003; 1 6 1296 1303
115. Chung A. WY, Radomski A., Alonso-Escolano D., et al. Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J Pharmacol: 2004; 143 7 845 855
116. von Brühl M-L, Stark K., Steinhart A., et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med: 2012; 209 4 819 835
117. Yokoyama S., Ikeda H., Haramaki N., Yasukawa H., Murohara T., Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol: 2005; 45 8 1280 1286
118. Zhang X., Zhan D., Shin H. Y. Integrin subtype-dependent CD18 cleavage under shear and its influence on leukocyte-platelet binding. J Leukoc Biol: 2013; 93 2 251 258
119. Zeller J. A., Lenz A., Eschenfelder C. C., Zunker P., Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol: 2005; 25 7 1519 1523
120. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation: 2002; 106 23 2894 2900
121. Di Serafino L., Sarma J., Dierickx K., et al. Monocyte-platelets aggregates as cellular biomarker of endothelium-dependent coronary vasomotor dysfunction in patients with coronary artery disease. J Cardiovasc Transl Res: 2014; 7 1 1 8
122. Rutten B., Tersteeg C., Vrijenhoek J. E., et al. Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques. PLoS ONE: 2014; 9 8 e105019
123. Michelson A. D., Barnard M. R., Krueger L. A., Valeri C. R., Furman M. I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation: 2001; 104 13 1533 1537
124. Hua V. M., Abeynaike L., Glaros E., et al. Necrotic platelets provide a procoagulant surface during thrombosis. Blood: 2015; 126 26 2852 2862
125. Hua V. M., Chen V. MY. Procoagulant platelets and the pathways leading to cell death. Semin Thromb Hemost: 2015; 41 4 405 412
126. Prodan C. I., Stoner J. A., Cowan L. D., Dale G. L. Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction. J Cereb Blood Flow Metab: 2013; 33 2 287 292
127. Kirkpatrick A. C., Tafur A. J., Vincent A. S., Dale G. L., Prodan C. I. Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis. Stroke: 2014; 45 10 2995 3001
128. Rechner A. R. Platelet function testing in clinical diagnostics. Hamostaseologie: 2011; 31 2 79 87
129. Gorog D. A., Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol: 2013; 61 21 2115 2129
130. E. Kehrel B., F. Brodde M. State of the art in platelet function testing. Transfus Med Hemother: 2013; 40 2 73 86
131. Paniccia R., Priora R., Liotta A. A., Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag: 2015; 11 133 148
132. Ghasemzadeh M., Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res: 2013; 131 3 191 197